Wenchang Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenchang Peng has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Bin Zheng
Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, 300072, China
2 shared publications - Bowen Li
Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China
2 shared publications Hua Wang
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
2 shared publications- Tao Wang
School of Life Sciences, Tianjin University, Tianjin, China
2 shared publications - Chongyu Tian
Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, China
1 shared publication - Gong Cheng
Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 25 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Bioorthogonal optimized virus immuno-nanomedicine (BOVIN)
The failure of tumour immunotherapy can be attributed to two primary factors: the limited immunogenicity of tumour cells and the immunosuppressive characteristics of the tumour microenvironment. Recent research indicates that cancer patients infected with respiratory viruses exhibit a positive antitumour response, as the activated host immune system. Here we show a bioorthogonal optimized virus immuno-nanomedicine (BOVIN) that uses nonpathogenic recombinant virus immuno-nanomedicine (VIN) for the targeted therapy of solid tumours. The influenza viruses (A/WSN/1933(WSN)) induce immunogenic cell death (ICD) in tumour cells by triggering a stress response mediated by integrated mitochondrial dysregulation. Furthermore, the surface modification of WSN with lactate oxidase enables the consumption of lactate to produce hydrogen peroxide, which synergistically enhance ICD activation. This leads to the attraction and significant activation of antigen-presenting cells in the tumour region through the exposure of calreticulin and secretion of high mobility group box 1. Additionally, the BOVIN triggers the tumour ICD, significantly enhances CD8+ T-cell tumour infiltration, strengthens the sensitivity of immune checkpoint blockers, and thus activates anti-tumour immune memory to effectively inhibit tumour recurrence after surgery. In conclusion, bioorthogonal nonpathogenic recombinant VIN reverses the immunosuppressed state of malignant cells, offering potential for improved tumour immunotherapy.
- 25 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessBioorthogonal optimized virus immuno-nanomedicine (BOVIN)
The failure of tumour immunotherapy can be attributed to two primary factors: the limited immunogenicity of tumour cells and the immunosuppressive characteristics of the tumour microenvironment. Recent research indicates that cancer patients infected with respiratory viruses exhibit a positive antitumour response, as the activated host immune system. Here we show a bioorthogonal optimized virus immuno-nanomedicine (BOVIN) that uses nonpathogenic recombinant virus immuno-nanomedicine (VIN) for the targeted therapy of solid tumours. The influenza viruses (A/WSN/1933(WSN)) induce immunogenic cell death (ICD) in tumour cells by triggering a stress response mediated by integrated mitochondrial dysregulation. Furthermore, the surface modification of WSN with lactate oxidase enables the consumption of lactate to produce hydrogen peroxide, which synergistically enhance ICD activation. This leads to the attraction and significant activation of antigen-presenting cells in the tumour region through the exposure of calreticulin and secretion of high mobility group box 1. Additionally, the BOVIN triggers the tumour ICD, significantly enhances CD8+ T-cell tumour infiltration, strengthens the sensitivity of immune checkpoint blockers, and thus activates anti-tumour immune memory to effectively inhibit tumour recurrence after surgery. In conclusion, bioorthogonal nonpathogenic recombinant VIN reverses the immunosuppressed state of malignant cells, offering potential for improved tumour immunotherapy.
- Top Cited Papers
- 26 November 2024
- Published by Springer Nature in Nature Materials
- Vol. 24 (4) , 637-648
Inhalable nanocatalytic therapeutics for viral pneumonia
Pneumonia is a ubiquitous disease caused by viral and bacterial infections, characterized by high levels of reactive oxygen species in inflamed areas. Therapeutic strategies targeting reactive oxygen species levels in pneumonia have limited success due to the intricate nature of lung tissues and lung inflammatory responses. Here we describe an inhalable, non-invasive therapeutic platform composed of engineered cerium-based tannic acid nanozymes bound to a self-assembling peptide. In vitro and in vivo studies show that the nanozyme is internalized mostly by activated macrophages and epithelial cells in the inflamed sites. In the oxidative environments of a mouse model of viral pneumonia, nanozyme aggregates into catalytically active structures that reduce reactive oxygen species levels and inflammatory cytokine production and promote macrophage polarization to the prohealing (M2) phenotype. Moreover, the nanozyme attenuates bacterial inflammation and reduces tissue damage in a mouse viral pneumonia model with secondary bacterial infection. Overall, this nanozyme platform is a promising strategy for treating pneumonia and its associated conditions.
- 26 November 2024
- Published by Springer Nature in Nature Materials
- Vol. 24 (4) , 637-648
Top Cited PapersInhalable nanocatalytic therapeutics for viral pneumonia
Pneumonia is a ubiquitous disease caused by viral and bacterial infections, characterized by high levels of reactive oxygen species in inflamed areas. Therapeutic strategies targeting reactive oxygen species levels in pneumonia have limited success due to the intricate nature of lung tissues and lung inflammatory responses. Here we describe an inhalable, non-invasive therapeutic platform composed of engineered cerium-based tannic acid nanozymes bound to a self-assembling peptide. In vitro and in vivo studies show that the nanozyme is internalized mostly by activated macrophages and epithelial cells in the inflamed sites. In the oxidative environments of a mouse model of viral pneumonia, nanozyme aggregates into catalytically active structures that reduce reactive oxygen species levels and inflammatory cytokine production and promote macrophage polarization to the prohealing (M2) phenotype. Moreover, the nanozyme attenuates bacterial inflammation and reduces tissue damage in a mouse viral pneumonia model with secondary bacterial infection. Overall, this nanozyme platform is a promising strategy for treating pneumonia and its associated conditions.